Alto Neurosciences is halting work on its schizophrenia prospect after the brain-penetrant drug flunked a phase 2 study. The Bay Area biotech evaluated 10 days of treatment with t ...
Alto Neuroscience, Inc. (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on precision medicines for neuropsychiatric disorders, today announced topline data from its Phase 2 ...
US-based biopharmaceutical company Spinogenix has concluded the enrolment of patients in its Phase II clinical trial of tazbentetol (previously known as SPG302), a synaptic regenerative treatment for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results